In a significant move to advance endovascular interventions, Johnson & Johnson (J&J) has officially commenced enrolment for its SKYWARD investigational device exemption (IDE) clinical programme. This ambitious research initiative is designed to evaluate the safety and clinical efficacy of the Shockwave SkyRunner Carotid Intravascular Lithotripsy (IVL) system, a specialized device engineered to address one of the most persistent challenges in vascular medicine: severe calcification in the carotid arteries.
The inaugural patient was successfully treated at the McLaren Bay Region Hospital in Bay City, Michigan, marking the beginning of a multi-year effort that could fundamentally alter how physicians approach stroke prevention in high-risk populations.
The Clinical Imperative: Addressing a Leading Cause of Stroke
Carotid artery disease (CAD) represents a critical public health concern, accounting for approximately 30% of all ischemic strokes. The condition is characterized by the accumulation of plaque—specifically calcium deposits—within the carotid arteries, which are the primary vessels responsible for delivering oxygenated blood to the brain.
When these arteries become heavily calcified, they pose significant procedural risks for surgeons. Traditional balloon angioplasty and stenting in calcified vessels are often fraught with complications, including vessel dissection, poor stent expansion, and distal embolization, where plaque fragments break off and travel to the brain, potentially triggering a stroke.
By utilizing IVL technology, J&J aims to "crack" the calcium safely before stent placement. This lithotripsy process uses sonic pressure waves to disrupt the hardened calcium, allowing the vessel to become more compliant. This ensures better stent apposition and reduces the trauma associated with traditional mechanical dilation.
Chronology of the SKYWARD Programme
The launch of the SKYWARD programme is the culmination of years of development and strategic acquisition. The timeline of this initiative reflects the evolution of Shockwave Medical’s technology under the J&J umbrella:
- Pre-Acquisition Development: Following the success of Shockwave’s IVL technology in coronary and peripheral artery applications, the company identified a critical need for a carotid-specific platform.
- Engineering Phase: The SkyRunner device was specifically designed with rapid-exchange capabilities and tailored sizing profiles to accommodate the anatomical nuances of both transcarotid and transfemoral access points.
- Regulatory Alignment: J&J engaged in extensive dialogue with regulatory bodies to define the IDE study parameters, ensuring the data generated would be robust enough to support future market authorization.
- Patient Enrollment Initiation (June 2026): The first patient procedure at McLaren Bay Region Hospital marks the transition from pre-clinical and pilot testing to large-scale, prospective multi-centre investigation.
Supporting Data and Study Design
The SKYWARD programme is not a singular study but a comprehensive framework consisting of two primary prospective, multi-centre, single-arm IDE studies. These studies are bifurcated to address the two most common routes of vascular access: the transcarotid approach and the transfemoral approach.
Key Study Metrics:
- Total Enrollment: Up to 320 subjects are expected to be enrolled across both arms of the study.
- Site Distribution: The programme will leverage as many as 50 clinical sites across the United States, ensuring a diverse patient demographic and a wide range of institutional expertise.
- Roll-in Patients: To account for the learning curve associated with new medical device adoption, the protocol includes an additional 25 roll-in patients per arm.
- Longitudinal Monitoring: The programme is committed to extensive clinical rigor, with long-term follow-up scheduled for all participants for a duration of five years. This will provide unprecedented data on the durability of the treatment and long-term stroke prevention outcomes.
The national principal investigators leading this effort are an elite cohort of vascular experts: Drs. William Gray, Nicolas Mouawad, Peter Schneider, and Peter Soukas. Their combined expertise ensures that the trial is conducted with the highest standards of procedural oversight and data integrity.
Official Responses and Strategic Vision
The leadership at Johnson & Johnson and Shockwave Medical views the SKYWARD programme as a cornerstone of their cardiovascular strategy.
Nick West, Chief Medical Officer of the J&J unit Shockwave Medical, emphasized that the programme is a direct response to feedback from the clinical community. "Shockwave IVL has become a trusted standard for modifying vascular calcification in coronary and peripheral interventions, and we believe its potential extends well beyond where it’s used today," West stated.
He further elaborated on the philosophy behind the device’s creation: "SKYWARD reflects what happens when innovation is driven in lockstep with physicians’ needs. We listened to what they told us they needed in the carotid space and responded with a first-of-its-kind, purpose-built platform designed for calcific carotid disease. This clinical programme is about generating the evidence physicians have asked for so we can expand treatment options and advance outcomes for patients with challenging calcific carotid disease."
Implications for the Medical Device Landscape
The implications of the SKYWARD programme extend far beyond the operating room.
1. Shift in Standards of Care
If the SkyRunner system demonstrates the expected improvements in safety and stent outcomes, it could shift the standard of care for patients who are currently deemed at "increased risk" for carotid endarterectomy (CEA). These are patients whose anatomical profiles make traditional open surgery dangerous, yet who currently have limited options for safe stenting due to severe calcification.
2. Economic and Manufacturing Context
The initiation of the SKYWARD programme coincides with a broader, aggressive investment strategy by Johnson & Johnson. Earlier this month, the company announced a $1 billion investment to bolster its vision manufacturing capabilities in Florida. This is part of a monumental $55 billion capital allocation plan aimed at expanding J&J’s total US manufacturing footprint through 2029.
By integrating advanced medical device manufacturing with high-stakes clinical research like SKYWARD, J&J is positioning itself to dominate the high-growth segments of cardiovascular and interventional medicine.
3. The Future of Vascular Interventions
The use of sonic pressure waves to treat vascular disease has already proven transformative in peripheral artery disease (PAD) and coronary artery disease. By applying this technology to the carotid space, J&J is tackling one of the most technically demanding areas of the human anatomy. Success here would not only provide a life-saving tool for patients but also validate the broader application of IVL technology in complex, calcified vasculature across the entire human body.
Conclusion
The commencement of the SKYWARD programme marks a defining moment for J&J and for the thousands of patients suffering from calcified carotid disease. By combining rigorous scientific inquiry, purpose-built hardware, and a vast network of clinical experts, the company is attempting to solve a problem that has long plagued vascular surgeons.
As the studies progress over the coming five years, the medical community will be watching closely. Should the Shockwave SkyRunner prove as effective as preliminary data suggests, it will represent a significant victory for patient safety, potentially reducing the incidence of strokes worldwide and setting a new benchmark for endovascular innovation in the 21st century.
The integration of this programme into J&J’s wider manufacturing and investment roadmap underscores a commitment to long-term dominance in the medical device sector, signaling to competitors and stakeholders alike that the company is prepared to invest heavily in the evidence-based future of medicine.
About the Author
